Saturna Capital’s Filana Therapeutics FLNA Stock Holding History

Saturna Capital’s Portfolio FLNA Stock Details FLNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-16,000	Closed	-$669K	–	156
2022 Q3	$669K	Hold	16,000	–	–	0.02%	115
2022 Q2	$450K	Sell	16,000 -37,375	-70%	-$944K	0.01%	125
2022 Q1	$1.98M	Sell	53,375 -2,100	-4%	-$89K	0.04%	84
2021 Q4	$2.42M	Buy	55,475 +75	+0.1%	+$3.93K	0.04%	83
2021 Q3	$3.44M	Buy	55,400 +300	+0.5%	+$25K	0.07%	69
2021 Q2	$4.71M	Hold	55,100	–	–	0.1%	66
2021 Q1	$2.48M	Buy	55,100 +35,100	+176%	+$1.38M	0.06%	76
2020 Q4	$136K	Buy	+20,000	New	+$179K	﹤0.01%	171

Other funds holding FLNA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

GCM

Gallacher Capital Management Lone Tree, Colorado $178M AUM 29.29% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Saturna Capital's FLNA Position: Q4 2022 in Review

Saturna Capital sold out of Filana Therapeutics (FLNA) in Q4 2022, closing a stake of 16,000 shares — an estimated $669K sold.

Saturna Capital first reported a position in FLNA in Q4 2020 and held it in 8 quarters. The position peaked at $4.71M in Q2 2021. 153 funds tracked by Wall St. Rank hold FLNA as of Q4 2022.

Saturna Capital reported no remaining Filana Therapeutics position as of Q4 2022 after selling out during the quarter.
Saturna Capital sold 16,000 Filana Therapeutics shares in Q4 2022, an estimated $669K.
Saturna Capital first reported a position in Filana Therapeutics in Q4 2020 and held it in 8 quarters.
Saturna Capital's Filana Therapeutics position peaked at $4.71M in Q2 2021.
153 funds tracked by Wall St. Rank held Filana Therapeutics as of Q4 2022.

Based on Saturna Capital's 13F filing for Q4 2022, filed 9 Feb 2023.